OTC.NewDirections, welcomes you to 2014 with the first bulletin of the year, where we are looking at the latest in clinical trial data transparency. The UK government has said it is “surprised and concerned” that data is routinely withheld from the medical and academic community. Meanwhile, a provisional agreement between the European Parliament and Council of Ministers would require both Pharmaceutical companies and academic researchers to upload all their results to a publicly accessible database. Continue reading
For our final issue of 2013, INSIGHT North America has put together a round-up of the hot topics that are driving growth (and decline) in North America’s OTC market, including dedicated sections on Rx-to-OTC switch, personalised health, delivery format innovation, the impact of scientific studies on supplements and mHealth. Readers will also enjoy a review of A+P spending in the US market in 2013 and expert commentary on the latest regulatory changes in Canada.
We’re also excited to announce that all INSIGHT subscribers will be able to enjoy an improved search function from 2014 onwards. An updated design and better integration with the Nicholas Hall & Company website will make it easier to search through the INSIGHT archive for the brands, marketers and topics of specific interest to you. We hope that you enjoy this upgrade to your service and send you very best wishes for the holiday period.
Find out more about INSIGHT by visiting our website.
In this week’s OTC.NewDirections Editor’s Comment, I will be looking at the latest developments in clinical trial regulations and how they are becoming more transparent in the nature. I will also be highlighting the changes for branded supplements and how they are beginning to show their benefits to the customer.
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed its concerns with the European Medicines Agency’s (EMA) draft policy on the publication and access to trial data, while in the UK, the Health Research Authority (HRA) is set to begin implementing plans to ensure trial information is publicly available.
In scientific developments, Sinetrol X-Pur (Fytexia) is showing that it could be a “viable option” for weight management and improving inflammatory, glycaemic and oxidative status. Branded ingredient Verisol (Gelita) has been found to significantly improve women’s skin elasticity and SesaVita (Olive Bioscience) may be beneficial in prediabetes management and mild-to-moderate hyperlipidemia. To find out why, read tomorrow’s bulletin.
For more information on these stories see our latest issue of OTC.NewDirections.